Eli Lilly gets FDA green light for Emgality for migraine
Eli Lilly has received the Food and Drug Administration’s blessing for Emgality (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults.
Migraine is a disabling, neurologic disease that affects more than 30 million American adults, according to the company.
"Despite the devastating impact of migraine, only about 10% of people living with the disease are currently taking a preventive treatment," Lilly bio-medicines president Christi Shaw said, in a statement. "For more than two decades, Lilly has recognized this unmet need, and we have worked tirelessly to develop a new option specifically designed for the prevention of migraine. With this approval, we are thrilled to offer a preventive treatment option to adults living with this disease."
Migraine is a disabling, neurologic disease that affects more than 30 million American adults, according to the company.
"Despite the devastating impact of migraine, only about 10% of people living with the disease are currently taking a preventive treatment," Lilly bio-medicines president Christi Shaw said, in a statement. "For more than two decades, Lilly has recognized this unmet need, and we have worked tirelessly to develop a new option specifically designed for the prevention of migraine. With this approval, we are thrilled to offer a preventive treatment option to adults living with this disease."